What are the recommended treatment options for aspergillosis?

Treatment of Aspergillosis

For invasive pulmonary aspergillosis (IPA), voriconazole is the first-line treatment of choice, with isavuconazole and liposomal amphotericin B as primary alternatives 1.

Invasive Aspergillosis Treatment Algorithm

First-Line Therapy for IPA

Voriconazole is the preferred agent based on the strongest evidence 1:

• Loading dose: 6 mg/kg IV every 12 hours for 1 day
• Maintenance: 4 mg/kg IV every 12 hours
• Oral option: 200-300 mg every 12 hours (weight-based dosing)
• Critical point: Therapeutic drug monitoring is mandatory for voriconazole 2

Primary alternatives when voriconazole cannot be used 1, 3:

• Isavuconazole: 200 mg every 8 hours for 6 doses, then 200 mg daily (may have better safety profile than voriconazole) 4
• Liposomal amphotericin B: 3-5 mg/kg/day IV

Combination Therapy Considerations

Combination therapy with voriconazole plus echinocandin is NOT routinely recommended for initial treatment 1, 5. The 2024 American Thoracic Society guideline provides only a conditional recommendation for combination therapy based on low-quality evidence 5. Reserve combination therapy for:

• Salvage situations after treatment failure
• Individual patients with severe disease at clinician discretion
• Breakthrough infections on azole prophylaxis (switch drug classes) 1

Salvage Therapy Options

When first-line therapy fails 1:

• Posaconazole (oral suspension 200 mg TID; tablet 300 mg BID day 1, then 300 mg daily)
• Echinocandins as add-on: Caspofungin (70 mg day 1, then 50 mg daily), micafungin (100-150 mg daily), or anidulafungin
• ABLC (amphotericin B lipid complex): 5 mg/kg/day IV
• Switch to different drug class if breakthrough occurs on azole prophylaxis 1

Treatment Duration

• IPA: Minimum 6-12 weeks depending on disease severity and immune status 2
• Continue until clinical and radiological resolution
• Extend duration in persistently immunocompromised patients

Site-Specific Invasive Aspergillosis

CNS Aspergillosis

• Same antifungal regimen as IPA 1
• Critical caveat: Highest mortality among all aspergillosis patterns
• Monitor for drug interactions with anticonvulsants (especially with voriconazole)

Invasive Sinus Aspergillosis

• Same medical therapy as IPA 1
• Mandatory surgical debridement as adjunct to antifungals 6

Cardiac Aspergillosis (Endocarditis/Pericarditis)

• Same antifungal regimen 1
• Surgical resection required for endocardial lesions
• Pericardiectomy usually needed for pericarditis

Aspergillus Osteomyelitis/Septic Arthritis

• Same antifungal therapy 1
• Surgical debridement of devitalized bone/cartilage essential for cure

Chronic Pulmonary Aspergillosis (CPA)

When to Treat CPA

Treat if ANY of the following 1:

• Pulmonary symptoms present
• Constitutional symptoms (weight loss, significant fatigue)
• Progressive loss of lung function
• Radiographic progression

Observation acceptable for asymptomatic patients without functional decline—follow every 3-6 months 1.

CPA Treatment Regimen

Preferred oral agents 1:

1. Itraconazole (first-line, strong recommendation)
2. Voriconazole (first-line, strong recommendation)
3. Posaconazole (third-line for adverse events or failure)

Treatment duration: Minimum 6 months; may require lifelong therapy for progressive disease 1

For treatment failures or triazole resistance 1:

• IV micafungin, caspofungin, or amphotericin B (all weak recommendations)
• Consider surgical resection for localized disease unresponsive to medical therapy, especially with pan-azole resistance

CPA Complications

Hemoptysis management 1:

1. Oral tranexamic acid (first-line)
2. Bronchial artery embolization
3. Antifungal therapy to prevent recurrence
4. Surgical resection if above measures fail

Single Aspergilloma

Asymptomatic with stable cavity: Observe without treatment 1

Symptomatic (especially significant hemoptysis): Surgical resection unless contraindicated 1

Perioperative antifungals not routinely required unless moderate spillage risk 1.

Allergic Bronchopulmonary Aspergillosis (ABPA)

Treatment approach 1, 7:

1. Topical nasal steroids (reduce symptoms, increase time to relapse, especially post-surgery)
2. Polypectomy and sinus washout (optimal for symptom control and remission, though relapse is frequent)
3. Oral mold-active triazoles for refractory/rapidly relapsing disease (only partially effective)
4. Monoclonal antibodies (omalizumab, mepolizumab) for severe cases 7

Prophylaxis Strategies

Lung Transplant Recipients

Mandatory prophylaxis 1:

• Duration: 3-4 months post-transplant
• Agents: Voriconazole, itraconazole, or inhaled amphotericin B
• Prefer systemic azoles over inhaled amphotericin for high-risk patients (mold colonization, fungal infections in explanted lungs, single-lung recipients)
• Reinitiate prophylaxis with immunosuppression augmentation (thymoglobulin, alemtuzumab, high-dose steroids)

Hematopoietic Stem Cell Transplant

Continue prophylaxis throughout chronic GVHD requiring corticosteroids >1 mg/kg/day prednisone equivalent for >2 weeks or other anti-GVHD therapies 1

Empiric Therapy in Neutropenic Fever

Recommended for prolonged neutropenia (>10 days) with persistent fever despite antibiotics 1:

• Lipid formulation amphotericin B (strong recommendation)
• Echinocandin (caspofungin or micafungin) (strong recommendation)
• Voriconazole (strong recommendation)

Biomarker-driven preemptive approach (galactomannan or β-D-glucan) is an acceptable alternative to empiric therapy, reducing unnecessary antifungal use without compromising survival 1

NOT recommended for anticipated short neutropenia (<10 days) unless other findings suggest invasive fungal infection 1

Critical Monitoring Parameters

• Voriconazole and posaconazole: Therapeutic drug monitoring mandatory 2
• Aspergillus-specific IgG: Levels >40 mg/L at treatment completion predict CPA relapse; patients with IgG <40 mg/L rarely relapse 8
• Serial imaging and cultures to guide treatment duration
• Drug interactions: Particularly important with voriconazole and anticonvulsants, immunosuppressants

Common Pitfalls to Avoid

1. Do not delay treatment while awaiting definitive diagnosis in high-risk patients with strong clinical suspicion 1
2. Do not use combination therapy routinely for initial IPA treatment—reserve for salvage 5
3. Do not forget therapeutic drug monitoring for voriconazole and posaconazole 2
4. Do not treat short-duration neutropenia empirically (<10 days) 1
5. Do not overlook surgical intervention when indicated (sinus disease, endocarditis, osteomyelitis, refractory aspergilloma) 1